MedTrace Logo

Biomarkers in Prostate Cancer Treated With SRP Following Failure of FAT

NCT03533998 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2018-05-23

No results posted yet for this study

Summary

The ability of genomic biomarkers to Measuring tumour aggressiveness, and facilitate the selection of therapies in patients who had salvage radical prostatectomy after focal therapy and predict the risk of biochemical recurrence BCR after focal therapy or RP.

Conditions

  • Prostatic Neoplasms

Sponsors & Collaborators

  • Institut Mutualiste Montsouris

    lead OTHER

Principal Investigators

  • Qusay Mandoorah, resident · Institut Mutualiste Montsouris

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-31
Primary Completion
2018-09-30
Completion
2018-09-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03533998 on ClinicalTrials.gov